Acura Pharmaceuticals (Acura Pharmaceuticals) Accounts Receivable : $0.16 Mil (As of Dec. 2021)

View and export this data going back to 1992. Start your Free Trial

What is Acura Pharmaceuticals Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Acura Pharmaceuticals's accounts receivables for the quarter that ended in Dec. 2021 was $0.16 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Acura Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2021 was 400.49.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Acura Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2021 was $-0.01.

Acura Pharmaceuticals Accounts Receivable Historical Data

The historical data trend for Acura Pharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acura Pharmaceuticals Accounts Receivable Chart

Acura Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Accounts Receivable

Get a 7-Day Free Trial

0.07

0.14

0.16

0.63

0.16

Acura Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Accounts Receivable	Get a 7-Day Free Trial															0.63	0.93	1.11	0.54	0.16

Acura Pharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Acura Pharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Acura Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2021 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.158	/	0.036	*	91
=	400.49

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Acura Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Acura Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2021 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.065	+	0.75 * 0.158	+	0.5 * 0	-	0.682
-	0	-	0)	/	65.093
=	-0.01

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Acura Pharmaceuticals Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Acura Pharmaceuticals's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Acura Pharmaceuticals (Acura Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acura Pharmaceuticals Inc (OTCPK:ACUR) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

616 N. North Court, Suite 120, Palatine, IL, USA, 60067

Website

http://www.acurapharm.com

Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.

Executives

Bruce F Wesson	director	1827 PACIFIC ST BROOKLYN NY 11233
William G Skelly	director	C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067
George K Ross	director	1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596
James F Emigh	officer: VP, Corporate Development
Immanuel Thangaraj	director	10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380
Robert A Seiser	officer: VP, Treasurer & Controller	C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067
Robert B Jones	officer: President & CEO	C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067
Albert W Brzeczko	officer: VP Pharmaceutical Sciences APT	C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067
Peter A Clemens	officer: Senior VP & CFO	C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233
Abuse Deterrent Pharma, Llc	10 percent owner	333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202
Claudius Llc	10 percent owner	C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
John Schutte	10 percent owner	9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233
Galen Partners Iii L P	10 percent owner	610 FIFTH AVE 5TH FL NEW YORK NY 10020
Galen Management, Llc	10 percent owner	680 WASHINGTON BLVD, STAMFORD CT 06901
Galen Employee Fund Iii Lp	10 percent owner	610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020